US FDA Communications Post-Gottlieb: No Slow-Down In Statements, But Attribution Changes
Executive Summary
Breakneck pace of press releases under former US FDA Commissioner Scott Gottlieb hasn’t abated in the early days of the Sharpless era – but the attribution has.
You may also be interested in...
US FDA Puts Spotlight On Alkermes' Violative Vivitrol Ad
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
US FDA Converges With Other Regulators On Insomnia Drug Warnings, But Broader Safety Disagreements Persist
US FDA will add boxed warnings to insomnia drugs, bringing it in line with other regulators, even as a study in JAMA Internal Medicine study indicates that national drug authorities often disagree more broadly over when to issue safety advisories.
US FDA Reorg: Defining The “Central” Purpose Of A Commissioner
Scott Gottlieb will formally implement a new structure for the Office of the Commissioner just days before he departs from the job. That may be odd timing, but the new structure is in many ways a perfect capstone for Gottlieb’s tenure.